Table 2 Details of the clinical, biological and treatment data collected during each follow-up visit
Month 0 | Month 3 | Month 6 | Month 12 | |
|---|---|---|---|---|
Patients attending the visit | 78 (100%) | 42 (65.6%) | 54 (84.4%) | 38 (59.4%) |
Serum urate (mg/dL) | 7.43 ± 2.33 | 6.57 ± 1.9 | 5.59 ± 1.56 | 5.63 ± 1.81 |
Ongoing ULT | 36 (46.2%) | 33 (78.5%) | 47 (87.1%) | 34 (89.4%) |
Ongoing flare prophylaxis | 25 (32.1%) | 20 (47.6%) | 27 (50%) | 16 (42.1%) |
Number of flares since M0 | N/A | 0.6 ± 1.3 | 0.7 ± 1.4 | 1.5 ± 3.3 |
Patients with at least 1 flare since M0 | N/A | 15 (35.7%) | 19 (35.2%) | 16 (42.1%) |
Number of flares since previous visit | N/A | 0.6 ± 1.3 | 0.3 ± 0.7 | 0.7 ± 1.6 |
Patients with at least 1 flare since previous visit | N/A | 15 (35.7%) | 9 (17%) | 12 (31.6%) |